Skip to main content

Retinal Disease

Ophthalmology
0
Pipeline Programs
2
Companies
7
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Ophthalmology is a $3.7B market with a mature, consolidating portfolio dominated by glaucoma treatments and emerging corneal/retinal therapies.

$3.7B marketMature→ Stable30 products15 companies

Key Trends

  • Glaucoma therapeutics (prostaglandin analogs, adrenergic agents) represent 60%+ of spending but face patent cliffs 2028-2034
  • Innovative mechanisms (NGF agonists, LFA-1 antagonists, RTKIs) gaining traction in dry eye and retinal disease segments
  • Heavy trial activity (2,656 total) skewed toward Phase 4 (369) and Phase 3 (442), indicating mature clinical development landscape

Career Verdict

Ophthalmology offers stable mid-career opportunities with strong Commercial and Medical Affairs salaries, but limited innovation catalysts and significant patent cliff risk warrant careful timing of entry.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#1LUMIGANDeclining
$697M
AbbVie·LOE_APPROACHING
#2OXERVATEStable
$493M
Unspecified·PEAK
#3XIIDRAStable
$473M
Bausch + Lomb·PEAK7.6yr
#4INLYTAGrowing
$467M
Pfizer·PEAK11.2yr
#5HUMIRADeclining
$258M
AbbVie·LOE_APPROACHING

Drug Class Breakdown

Prostaglandin Analogs (Bimatoprost)
$697M(19%)

mature, losing exclusivity

Nerve Growth Factor Agonists
$493M(13%)

peak growth in corneal disease

LFA-1 Antagonists (Dry Eye)
$473M(13%)

sustained peak sales

Receptor Tyrosine Kinase Inhibitors
$467M(13%)

expanding in retinal indications

Alpha-2 Adrenergic Agonists
$362M(10%)

mature, multiple LOE approaching

Combination Therapies (Brimonidine/Timolol)
$232M(6%)

mature, losing exclusivity

Complement Inhibitors
$223M(6%)

mature immunology approach

Career Outlook

Stable

Ophthalmology offers predictable mid-career growth with strong Commercial ($158K) and Medical Affairs ($247K) compensation but faces structural headwinds: patent cliffs 2028-2034 eliminate $97M in revenue, glaucoma franchise maturity limits blockbuster potential, and modest trial volume (2,656) signals incremental R&D expansion. Best suited for professionals seeking stable roles in established therapeutic areas rather than disruptive innovation.

Breaking In

Enter via Clinical Operations or Commercial analyst roles at CROs (Syneos 210 jobs) or large diagnostics players (Labcorp 904) to build domain expertise before targeting pharma MSL/Medical Affairs positions.

For Experienced Professionals

Experienced professionals should prioritize Medical Affairs and Market Access roles leveraging mature market knowledge; avoid product-specific expertise in glaucoma due to patent cliff concentration, and consider adjacent areas (retinal, corneal) where innovation catalysts remain.

In-Demand Skills

Glaucoma/dry eye clinical expertise and key opinion leader relationshipsRegulatory navigation for mature small-molecule formulations and device combinationsMarket access and reimbursement strategy (high generic/biosimilar pressure)

Best For

Medical Science Liaison (MSL) — strong $247K average salary, KOL interface criticalCommercial/Brand Manager — competitive $158K salaries, established product lifecycle managementClinical Operations Manager — high hiring volume (409 jobs), trial coordination in Phase 4-heavy pipeline

Hiring Landscape

$59K-$247K

Ophthalmology hiring (3,202 jobs) is distributed across diagnostics/devices (Labcorp 904, Abbott 348) and pharma commercial functions rather than concentrated in R&D. Top pharmaceutical employers (Pfizer 60, AstraZeneca 100, Regeneron 168) show modest pharma-specific headcount relative to market size, suggesting outsourced CRO and distributor dependency. Medical Affairs ($247K avg salary) commands premium compensation, signaling high barrier to entry but strong mid-career upside.

3,202
Open Roles
5
Companies Hiring
5
Departments

Top Hiring Companies

904Growing
348Stable
168Growing
219Stable

By Department

Clinical Operations(13%)
$150K
Commercial(10%)
$158K
Medical Affairs(3%)
$247K
R&D(6%)
$145K
Engineering(9%)
$112K

Clinical Operations and Commercial roles offer entry-level stability ($150K-$158K); Medical Affairs commands premium salaries ($247K) but requires advanced credentials; limited R&D hiring (207 jobs) suggests constrained innovation investment.

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Optos
OptosUK - Dunfermline
6 programs
Device: P200TxEN/A1 trial
OCTN/A1 trial
Optos P200TEN/A1 trial
P200TEN/A1 trial
P200TxEN/A1 trial
+1 more programs
Active Trials
NCT04003831Completed26Est. Jan 2021
NCT07149740Recruiting180Est. May 2026
NCT03868462Completed137Est. Sep 2019
+3 more trials
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
SPECTRALISN/A1 trial
Active Trials
NCT04661124Completed88Est. Apr 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
OptosOCT
OptosP200TxE
Heidelberg PharmaSPECTRALIS
OptosP200TxE
OptosDevice: P200TxE
OptosOptos P200TE
OptosP200TE

Clinical Trials (7)

Total enrollment: 591 patients across 7 trials

Data Gathering for A10900

Start: Jun 2025Est. completion: May 2026180 patients
N/ARecruiting

P200TxE Diseased Eye Image Collection

Start: Jan 2024Est. completion: Dec 2024100 patients
N/ARecruiting

Evaluation of the Heidelberg Engineering SPECTRALIS With Flex Module for In-vivo Imaging in the Supine Position

Start: Dec 2020Est. completion: Apr 202488 patients
N/ACompleted

Study Comparing the P200TxE and P200DTx

Start: Jun 2019Est. completion: Jan 202040 patients
N/ACompleted
NCT04003831OptosDevice: P200TxE

Navigated OCT Imaging With the P200TxE

Start: Jun 2019Est. completion: Jan 202126 patients
N/ACompleted
NCT03868462OptosOptos P200TE

Optos P200TE Agreement and Precision Study

Start: Feb 2019Est. completion: Sep 2019137 patients
N/ACompleted

Side-by-Side Comparison of P200TE and Spectral OCT/SLO on Diseased Eyes

Start: Sep 201620 patients
N/AUnknown

Related Jobs in Ophthalmology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 actively recruiting trials targeting 591 patients
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.